Obermatt
See Similar Stocks →

Praxis Precision Medicines

NSQ:PRAX · US74006W2070
BiotechnologySmall

360

37
Medium confidence — indicative
Profit price65
Cash yield1
Price/Sales16
Price/Book24
Return on Capital32
Cash Return on Capital49
Return on Equity41
Profit margins16

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth4
Long-Term EPS Growth22
Reinvestment74
Price momentum98
Debt load100
Refinancing69
Debt Payback1
Liquidity16
Analyst ratings26
Opinion Changes50
Price Target Upside100
Market mood35
Value Creation5/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Praxis Precision Medicines doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees176
Websitepraxismedicines.com
ISINUS74006W2070
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyPsychiatryGeneticsNeuroscienceCentral Nervous SystemAlternative MedicineBiotechnologyHealth CareMedical

Description

Praxis Precision Medicines, Inc. (Praxis), a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company is apply…

Analysis

Middle-of-the-road

Praxis Precision Medicines, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 5/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
89
2026

All-time high

89

Jun 2026

All-time low

55

Mar 2026

Average rank

72

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
16
—
—
—
Price/Earnings
84
—
—
—
Price/Book
24
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
55
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Praxis Precision Medicines with its peers
Monte Rosa Therapeutics
NSQ:GLUE
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Monopar Therapeutics
NAQ:MNPR
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Nuvalent
NSQ:NUVL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →